Humacyte, Inc. Common Stock
Here’s whether Humacyte, Inc. Common Stock (HUMA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+14.36% over 10 days); RSI 50 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -56.2%; 3-month momentum negative (-5.8%); rising volume on a downtrend (distribution, 1.17x avg). Currently 62.9% off its 52-week high. Score: -1/7.
HUMA is trading below its 200-day MA ($1.20) — a key warning sign the longer-term trend is under pressure. An RSI of 50.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -56.2% compares to +22.9% for SPY (trailed the market by 79.1%). The current 62.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.